Abediterol

Abediterol
Clinical data
Routes of; administration	Inhalation
ATC code	None;
Pharmacokinetic data
Elimination half-life	24.3 hours
Identifiers
	IUPAC name 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
CAS Number	915133-65-2;
PubChem CID	11962616;
IUPHAR/BPS	9326;
ChemSpider	10136846 ;
UNII	QXA167CM6F;
KEGG	D10219 ;
ChEBI	CHEBI:142077;
ChEMBL	ChEMBL3039530 ;
CompTox Dashboard (EPA)	DTXSID60238605 ;
Chemical and physical data
Formula	C25H30F2N2O4
Molar mass	460.522 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2;
	InChI InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 ; Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N ;

Abediterol (INN;^[2] development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed.

History

Abediterol was under development by the Spanish pharmaceutical company Almirall and reached Phase II clinical trials,^[3]^[4] but was discontinued in 2021.^[5] Its coformulation with mometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.^[6]

Mechanism of action

Abediterol acts as a dual β₂ adrenergic agonist^[7]^[8] and muscarinic antagonist and is classified as an ultra-long-acting β₂ agonist (ultra-LABA).^[9]

References

^ Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S (December 2014). "First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist". Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355. PMID 24989946. S2CID 20959248.
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.
^ Product development pipeline, Almirall
^ "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.
^ "Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 6 February 2024.
^ "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 6 February 2024.
^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.
^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.
^ Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S (October 2014). "Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–9. doi:10.1016/j.rmed.2014.08.005. PMID 25256258.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S (December 2014). "First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist". Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355. PMID 24989946. S2CID 20959248.

[2] "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.

[3] Product development pipeline, Almirall

[4] "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.

[5] "Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 6 February 2024.

[6] "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 6 February 2024.

[7] "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.

[8] "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.

[9] Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S (October 2014). "Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–9. doi:10.1016/j.rmed.2014.08.005. PMID 25256258.

[1]